Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | STK4 | Q13043 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16671742 | 0.79 | FGFR4 (0.47) | FGFR4S1PR2MAP4K1AR | |
| SCHEMBL23089666 | 0.78 | GRM4 (0.42) | CNR2FGFR4MAPK8MAPK9S1PR2 | |
| SCHEMBL16671196 | 0.76 | FGFR4 (0.60) | FGFR4 | |
| SCHEMBL16671066 | 0.76 | XDH (0.41) | CNR2FGFR4MAPK8MAPK9S1PR2 | |
| SCHEMBL16671048 | 0.76 | FGFR4 (0.55) | FGFR4 | |
| SCHEMBL8081930 | 0.75 | MAPK1 (0.38) | CNR2FGFR4ARKDM4ELRRK2 | |
| SCHEMBL16671033 | 0.74 | FGFR4 (0.60) | FGFR4 | |
| SCHEMBL7213409 | 0.73 | MAPK1 (0.39) | CNR2FGFR4ARKDM4EGLA | |
| SCHEMBL16670780 | 0.73 | FGFR4 (0.53) | FGFR4 | |
| SCHEMBL23586637 | 0.71 | MAPK1 (0.38) | CNR2FGFR4S1PR2ARKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3060563-B1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2018-05-02 | — | — | EP | disclosed |
| US-9896449-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20170066766-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2017-03-09 | — | — | US | disclosed |
| US-9533988-B2 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2017-01-03 | — | — | US | disclosed |
| EP-3060563-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | Novartis AG (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2016-04-14 | — | — | US | disclosed |
| WO-2015059668-A1 | RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102092-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | CNR2 1951/4885FGFR4 1/4885MAPK8 558/4885 |
| US-20170066766-A1 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | CNR2 1951/4885FGFR4 1/4885MAPK8 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.